Microtest and Antisoma Form Manufacturing Pact

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Agawam, MA (Mar. 26)-Contract manufacturing and testing laboratory Microtest signed a manufacturing deal with Antisoma to produce AS1411, a new drug being developed for the treatment of various cancers.

Agawam, MA (Mar. 26)-Contract manufacturer and testing laboratory Microtest (www.microtestlabs.com) signed a manufacturing deal with Antisoma (London, www.antisoma.com) to produce AS1411, a new drug being developed to treat various cancers.

Microtest will formulate and aseptically fill and finish AS1411 for Phase II clinical trials. Microtest also will perform stability testing on the product.

Microtest recently invested $7.5 million to expand its pharmaceutical testing services and fill-and-finish contract-manufacturing capabilities. The expansion included new pharmaceutical testing laboratories and new aseptic fill and finish manufacturing facilities.

Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Behind the Headlines episode 8
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Roger Viney, PhD, chief commercial officer for ICE Pharma
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Related Content